Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
Palliative care beneficial for patients with end-stage liver disease
CHARLOTTE, N.C. — Early palliative care referral would benefit patients with end-stage liver disease, resulting in fewer hospitalizations and more health care proxy assignments and code status changes, according to a presenter here.
Hyperferritinemia may indicate progression of liver disease, poor prognosis in MAFLD
CHARLOTTE, N.C. — Elevated ferritin correlated with an increased prevalence of cirrhosis — but not congestive heart failure — in patients with metabolic dysfunction-associated fatty liver disease, according to a presenter here.
Log in or Sign up for Free to view tailored content for your specialty!
Terlipressin reduced need for renal replacement therapy 1 year after liver transplant
CHARLOTTE, N.C. — A subgroup analysis of liver transplant patients with hepatorenal syndrome type 1 demonstrated that terlipressin decreased the need for renal replacement therapy up to 12 months following transplantation.
Recent injection drug use linked to HCV reinfection after DAA treatment
WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.
Global NAFLD prevalence rose 50% over 20 years, with hotspots in North Africa, Middle East
CHARLOTTE, N.C. —Nonalcoholic fatty liver disease prevalence rose more than 50% globally from 1990 to 2019, with African and Middle Eastern regions identified as hotspots, according to data presented at ACG Annual Scientific Meeting.
HCV care must ‘move away from the ivory tower’ to achieve elimination
WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.
Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050
WASHINGTON — An accelerated, nationally organized plan to eliminate hepatitis C virus in the United States could save more than 90,000 lives and nearly $60 billion by 2050, according to a health economics expert at The Liver Meeting.
ReLink programs led to treatment, engagement in nearly 20% of patients with untreated HCV
WASHINGTON — Implementation of care re-engagement programs led to the treatment of more than 700 patients with untreated hepatitis C virus infection who had been lost to follow-up, according to research presented at The Liver Meeting.
Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks
WASHINGTON — Bulevirtide monotherapy was safe and effective at 72 weeks for patients with hepatitis D virus-related compensated cirrhosis, with virological and clinical responses increasing over time, according to data presented here.
VIDEO: Women with NASH-cirrhosis at higher risk for polypharmacy to manage chronic pain
WASHINGTON — In a Healio video exclusive, Leen Al-Sayyed, MD, gastroenterology and transplant hepatology fellow at St. Louis University, reported women with nonalcoholic steatohepatitis-cirrhosis had an increased prevalence for polypharmacy.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read